Ruti Aga's Six-Year Ban: One Forged Prescription, Three Verification Failures, and the Arithmetic of Two Plus Four

A prescription carried the name of a clinic. The clinic did not exist. The 'doctor' who wrote it was a family member with no medical registration. Asked where the form had come from, he said it was an old prescription pad from a former workplace. The clinic named on the pad said it had never issued such a pad at all.

Three verifications. Three failures. And not one of them required a laboratory, a mass spectrometer or an uncertain test — just a phone call, a registry and an email. That is the most uncomfortable finding in this entire case. An athlete who won the 2026 Tokyo Marathon, whose record carries three second-place finishes at World Marathon Majors, found herself in the worst crisis of her career holding a document a trained clerk could have dismissed in ten minutes.

The Athletics Integrity Unit announced on Thursday a total sanction of six years. Two years for the presence of methylprednisolone, four for tampering. Read only the number and you have read the news and missed the story, because the substance at the centre of it did not belong to the category it was sold under.

I have spent years reading every doping decision as a ledger — which sanction came from which clause, how far it was backdated, at what age it landed, and what it took out of whatever career remained. Open the ledger on this one and a single line changes the arithmetic of the whole ruling. That line is pharmacological, and no verdict on this case is complete without it.

The substance, and the name it travelled under

Reports called methylprednisolone a 'prohibited steroid' and said WADA classifies it as performance enhancing. That sentence is technically wrong, and the error is not cosmetic. Methylprednisolone is a glucocorticoid, listed by WADA under class S9. Anabolic steroids sit in S1, and the distance between the two classes runs from sanction length all the way to public morality.

More important: under the current List, S9 glucocorticoids are prohibited in-competition only, and only by injection, oral or rectal routes. A therapeutic knee injection given out of competition is entirely lawful. It becomes a violation only if residues are still present in a sample taken at the competition. The hinge of this case is not 'steroid use'. The hinge is route and timing — which pathway, and how many days before the race.

One technical detail belongs here because coverage routinely drops it. In road races the in-competition testing window opens at 23:59 the day before the race. An injection given three days out that is still detectable on race day is a violation, whatever the intent behind it. The distance between treatment and violation is a pharmacokinetic calculation, not a moral one — and that is precisely where a credentialed team physician earns his fee and a relative with an old pad does not.

From Tokyo 2026 to a March race in China

Ruti Aga, 32, Ethiopia. My old files place her in the generation that put Ethiopian women's marathoning back at the centre of the sport across the 2026-19 seasons. The 2026 Tokyo Marathon title is hers, and it is the most solid asset that survives this case. Add three second places at World Marathon Majors. My own records carry a second place in Berlin 2026 and a time in that neighbourhood, but the AIU announcement released no mark, no split, no personal best. What is not in the record I will not enter against her name.

What is in the record: a sample taken after she won a half marathon in China in March returned positive. A knee injury was cited. A prescription was produced. The prescription was forged. A provisional suspension had been running from 10 September, and Thursday's decision counted the six-year ban from that same date — two years for presence, four for tampering.

A record-keeping gap deserves flagging. The announcement is silent on the year of the March race, the year the ban expires, the time she ran, and the quality of the field. When dates are incomplete, the first task is to separate the arithmetic that is certain from the inference that is not. The six-year total is certain. The rest of the ledger is not.

Two plus four: the account of a sanction

Six years sounds extraordinary. The structure is entirely ordinary. Two years for presence is a standard sanction, particularly where the substance is Specified and intent was not established. Four years for tampering is the Code's standard sanction. Add them and you get six.

But the sum carries news. Had the panel found grounds for No Significant Fault, the two-year presence sanction could have been reduced, in some cases to a reprimand. A total of six tells us the panel declined that relief. And the reason for the refusal was not the substance. It was the prescription.

Backdating to 10 September is not a discount either. Time served under provisional suspension counts against the ban; the athlete gains nothing in real terms. To be suspended from a date and have the ban counted from that same date is a word that sounds like mercy and measures zero.

I went looking for a number and found a system wearing it. Here the number is the gap between two and four. Two years for the molecule, four for the lie. The rulebook punished the paperwork twice as hard as the chemistry.

Injection, route, timing: the real hinge

Intra-articular or peri-articular methylprednisolone for knee synovitis is everyday sports medicine in distance runners. It is not a shadowy procedure. Marathoners carry chronic knee pathology the way sprinters carry hamstring history; it is a known load-bearing failure mode.

Which means a legitimate defence existed. If treatment genuinely happened, real records existed — a clinic bill, a prescriber's note, an injection date, a dose, and the interval to the race. With those, the athlete could have argued therapeutic out-of-competition use with residual detection. S9 leaves room for exactly that argument because it binds only in competition.

Instead the opposite happened. A prescription was manufactured, and manufacturing it destroyed the only defence that could have worked. There is a subtle turn here worth stating plainly: a forged document is itself circumstantial evidence of concealment intent. If the treatment was real, what needed hiding? That question stood in front of the panel, and it made any reduction on presence impossible.

I still have the sheet from Kalinga Stadium in 2026 on which I logged 214 Indian performances across four days. That exercise gave me a habit — walk any claim back to its document. Walk this one back and three independent verifications failed: the clinic's existence, the doctor's registration, the pad's authenticity. Three separate checks, one answer. When a single lie breaks across three registries, it stops being a mistake.

A forged prescription is a medical-governance audit

The real story here is not about the athlete. It is about the structure around her.

The prescriber was an unregistered family member. That is not a filing error; it is the signature of an athlete operating without a credentialed team physician. A marathoner with three Major second places and a Tokyo title whose staff includes not one registered doctor is less an athlete's negligence than a system's failure.

The second signal is TUE infrastructure. A properly managed athlete facing a dozen injections either holds a Therapeutic Use Exemption or observes WADA's route-specific washout. Neither appears to have happened — an inference, but one that follows from the fact that a forgery was attempted at all.

The third and least comfortable signal sits in the investigation. The four-year tampering sanction came from an interview, not from a document alone — from statements made under questioning. Language and interpretation conditions in AIU interviews with Ethiopian athletes have been a recurring point of friction. That does not exonerate anyone, but it points to a process where legal support and linguistic clarity are unevenly distributed. When two-thirds of a sanction rests on spoken words, the language, the interpreter and the presence of counsel are not marginal questions.

The appearance-fee market meets the testing market

In Indian athletics the real professional contract is not prize money but a sports-quota job — Railways, Services, state police. The East African road-running equivalent is the appearance fee. For a 2:18-2:20 marathoner the calendar looks like two or three Majors a year with Asian label races in between: decent start money, thin competition, controlled load.

China's label circuit has become the biggest node in that model. Large appearance budgets, deep East African fields, and now dense AIU scrutiny are converging in the same races. The appearance-fee economy and the testing economy are colliding. It is no accident that this tier produces the most cases: where money is thick and medical support is thin, exposure peaks.

Injury belongs in this picture. An injured marathoner faces a double squeeze — a start-fee contract and the fear that withdrawing costs the next invitation. The cheapest, most available tool for masking that pain is a glucocorticoid injection. That is not an excuse; it is a causal chain, and it terminates at the point where the athlete has no registered doctor and treatment becomes informal.

Ethiopian depth: a 2:18 performer is not selected automatically

Ethiopian women's marathoning is deep enough that a 2:18-2:20 athlete is not an automatic national pick. That is not the top of the pyramid; it is the first layer beneath it. And Aga carries no global championship medal — her three Major second places are commercial-tier results, not championship conversions. Selection rooms see that distinction first.

Two conclusions follow, and they do not contradict each other. The competitive landscape will not shift measurably; one athlete's removal does not change Ethiopian medal capacity. The governance landscape shifts a great deal. In a sport deep enough that a 2:18 runner is not a guaranteed pick, the duty to keep an athlete inside the system belongs to the system, not to her family.

Six years at 32 means a return at roughly 38. At that age, with a doping record, in that depth of field, no selector has a rational basis to pick her. Measured against the age curve, this is close to a lifetime ban. Somewhere between the stopwatch and the spreadsheet, a career is decided — and here it was ended not by a spreadsheet but by a prescription pad.

What survives? Tokyo 2026 survives. The violation is anchored to a later race, and absent a finding of earlier use, results before that date are not automatically annulled. The three Major second places survive. The March result and its prize money are very likely voided under standard AIU practice — but the announcement does not say so, and what is not written I will not rule.

Six years, one glucocorticoid, two contradictions

The first contradiction: six years for a substance with no proven endurance benefit. Glucocorticoids are misused to hide pain, not to build capacity. That is a smaller moral distance than an anabolic steroid, and collapsing the two into one category pushes reporting past the facts. Calling it a 'steroid' stops being a technical slip and becomes a narrative error.

The second is larger and sits inside the regulator's own logic. Two-thirds of this sanction is for paper. One reading: correct signalling, document fraud must cost more than presence. Another: incoherence, because expecting ethical rigour from an athlete with no registered doctor, no counsel and no interpreter while expecting nothing of the system that sent her out without one is a strange standard of justice.

Neither frame holds alone. This is not a simple story of AIU rigour, nor a simple story of disproportionate enforcement against African road runners. It is a case where the substance was small, the document was large, and the support structure was absent. Only one of those three was within the athlete's control, and she handled it worst.

One silence deserves noting. No Ethiopian federation statement appears anywhere in this matter; only the AIU has spoken. When an athlete receives six years and her national body says nothing, that silence is itself a fact. And the forgery of a prescription may be a criminal act in its own right; no national referral is mentioned. The AIU's jurisdiction ends there, and what lies beyond is dark.

A stadium remembers what a press release forgets

Across recent East African road-running cases a pattern repeats: the first violation involves a substance, the second and larger one involves its explanation. Caught once, a story is constructed. When the story breaks under verification, the sanction doubles. The enforcement frontier has moved from detection to document verification, and the instrument is not a laboratory but a registry.

That shift is not small. When a regulator's core competence becomes checking paperwork, its hit rate rises against athletes without good lawyers, good doctors and good interpreters. A European athlete with a genuine clinic invoice for the same mistake may never be caught at all. That is a question of equity, and this decision leaves it open.

One inference, flagged as an inference: the informal medical network that produced this prescription does not serve one athlete. Training clusters share agents and share 'doctors'. If one case reached this level, more are in the pipeline. The ledger never closes; it only changes hands.

What comes next

An appeal is live — typically within about 21 days of the reasoned decision to CAS. Overturning a document-based finding is hard when three separate verifications failed.

The real question is no longer when Ruti Aga returns. It is whether the next injured marathoner who needs a knee injection has a registered doctor or an old prescription pad. This decision settled the arithmetic of the sanction. It said nothing about who fills the medical vacuum in which the pad was made.

Two Julys, one athlete, and the arithmetic in between — here the arithmetic came to six years, and four of them were for a piece of paper.